Amen Sibtain: Profile

Mr Amen Sibtain is a consultant clinical oncologist specialising in the treatment of gastrointestinal, hepatobiliary and head and neck cancers, with a particular expertise in chemoradiotherapy and the latest radiotherapy techniques.

Following appointments at some of London's most renowned cancer centres, including the Royal Marsden and Mount Vernon Mr Sibtain is now based at The London Oncology Clinic on Harley Street, where he is Clinical Lead in Head and Neck Cancer. He was awarded his MD degree from the University of London for research in tumour hypoxia.

Mr Sibtain is a Past President of the Oncology Section of the Royal Society of Medicine, an examiner in oncology for the Royal College of Radiologists, an advisor to the Healthcare Commission, oncology advisor for BBC Drama, a member of the medical advisory panel for Cancer Backup, Programme Director for Clinical Oncology Specialist Training Committee for the London Deanery and Chairman of the Head and Neck Tumour Board for North East London.

Clinical interests

Highly experienced in the treatment of gastrointestinal, hepatobiliary and head and neck cancers, Dr Sibtain is skilled in the latest and most advanced therapies, including:

Intensity modulated radiotherapy (IMRT)

Intensity modulated radiotherapy (IMRT) uses advanced technology to shape a radiotherapy beam to the exact size and shape of a tumour, avoiding damage to surrounding healthy tissue.  Precise and varying doses can be applied to different areas of the tumour, maximising the effectiveness of the therapy and reducing side-effects.

Stereotactic radiosurgery

Stereotactic radiosurgery (also known as stereotactic radiotherapy) is another new technology to deliver targeted radiation to a tumour.  Most commonly used for small brain tumours such as acoustic neuroma, secondary brain tumours, menigioma and pituitary tumours, it involves the application of a very high dose of radiation to a very small precise area. 

Stereotactic radiosurgery can be delivered from specialised machines (Gamma Knife and CyberKnife), or from a conventional radiotherapy machine (linear accelerator) that has been adapted for the purpose.  Totally non-invasive and with an excellent record for successful treatment, it does not result in hair loss or nausea and patients can normally resume everyday activities within a couple of days.

Research interests

Mr Sibtain is the editor of the book 'Towards The Prevention of Cancer' (RSM Press: 2007). An early adopter of the Cyberknife, he has a particular interest in new radiotherapy techniques for the treatment of cancer.